Salivary Proline Rich Peptide Decreases Growth of Cancer Cells




Carcinoma of the breast is the second most common type of cancer among women and despite improved early detection, diagnosis and aggressive treatment approaches, consisting of surgery, radiotherapy and/or chemotherapy, carcinoma of the breast is still a great threat to human life. Currently, there is an incomplete knowledge of the molecular principles underlying the malignant progression as well as the development and maintenance of local recurrence and distant metastasis of this cancer type. There is also additional problems in rendering treatment of triple negative breast carcinomas, which are more aggressive than other types of breast cancer and respond poorly to treatments such as hormonal and Her2/neu receptor therapy.


Current research suggests that carcinoma of the breast may alter the protein profile of secretions produced by other exocrine tissues such as the lacrimal and salivary glands. One salivary protein that has been repeatedly found up-regulated among salivary proteomic analysis is the submaxillary gland androgen-regulated protein 3B (SMR3B; P02814).


Technology Advantages:

Studies showed that HCC38 cell line (triple negative breast cancer cell line) showed decreased growth when exposed to the low and high dose of the proline rich peptide segment (p1978) from the parent SMR3B protein. These results suggest that p1978 may have potential in treating triple receptor negative breast cancer.





Intellectual Property Status:

•       Patent application pending

•       Portfolio available for exclusive licensing


Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
For Information, Contact:
Ayesha Siddiqi
Technology Licensing Associate
University of Texas Health Science Center At Houston
© 2019. All Rights Reserved. Powered by Inteum